摘要
目的:观察吸入激素布地奈德治疗高原急性重症哮喘的效果。方法:40 例急性重症哮喘随机分为两组:吸入布地奈德组20 例,1 200~1 600 μg/d;口服强的松组20 例,40 mg/d。治疗前和治疗后1、3、5 、7、10 d 分别测呼气峰流速(PEF)。结果:治疗1 d,两组PEF% 预计值均显著增高,PEF日变异率显著降低(P< 0.05);治疗3 d,PEF% 预计值非常显著性增高,PEF日变异率非常显著性降低(P<0 .01) 。此后分别继续增高和降低,至第10 天吸入激素组和口服激素组PEF% 预计值分别由治疗前的41.7% ±9.2% 增至87 .6% ±11.3 % 和42.3% ±9.5 % 增至84 .0% ±10.2% ,PEF日变异率由33.7% ±12.8% 降至7.2% ±4 .0 % 和由35.5% ±15.1% 降至8.1% ±5.2% 治疗前后两组之间无显著性差异( P> 0.05) 。吸入激素组治疗1 d,症状明显缓解,3 d 全部控制。口服激素组除1 例在治疗第2 天病情恶化加用地塞米松10 mg 静注后控制,其余19 例均在治疗后1 d 症状明显缓解,3 d 全部控制。结论:吸入激素布地奈德气雾剂治疗高原急性重症哮喘有显?
Purpose:To evaluate the therapeutic effects of inhaling corticosteroid(budesonide) on acute severe asthma at plateaus.Methods:40 acute severe asthma patients were randomly divided into two groups:group 1( n =20) inhaled budesonide 1 200-1 600 μg/d;group 2( n =20) orally received prednisone 40 mg/d.After improvement of symptoms,the doses were gradually decreased,up to the 10th day,the former was decreased to 800 μg/d and the latter 10 mg/d.peak expiratory flow(PEF)was measured before and 1,3,5,7,10 days after treatment.Results:After one day of treatment,the predicate PEF% values in two groups were all increased significantly and the PEF daily change rate decreased obviously(all P <0.05).At the 10th day,in group 1,the former increased from 41.7%±9.2% to 87.6%±11.3% and the latter decreased from 33.7%±12.8% to 7.2%±4.0%(all P <0.01)and in group 2,the former increased from 42.3%±9.5% to 84.0%±10.2%,the latter decreased from 35.5%±15.1% to 8.1%±5.2%(all P <0.01).But there were no differences between these indexes of two groups before and after treatment(all P >0.05).Symptoms in 20 cases of group 1 and 19 of group 2 relieved at the 3rd day of treatment.Conclusion:Inhaling of budesonide is a very effective method for the treatment of acute severe asthma at plateaus.Its effects are same as those of oral prednisone treatment.
出处
《西北国防医学杂志》
CAS
1999年第4期263-265,共3页
Medical Journal of National Defending Forces in Northwest China